Diabetes (Type 1 & 2) and Haematopoietic stem-cell transplantation (HSCT): what the trial registry contains

Why this is studied in Diabetes (Type 1 & 2)

The registry entries here are dominated by type 1 diabetes, an autoimmune destruction of beta cells. Two distinct strategies appear: immune reset around new-onset disease, and beta-cell replacement from stem-cell-derived islets. The second is the most genuinely transformative line of work in the whole field, and it is also the one most often invoked by clinics offering something entirely different.

What HSCT means in this table

Haematopoietic transplantation is the oldest and most consequential cell therapy in medicine, with conditioning regimens that carry real mortality risk alongside genuine disease-modifying power. Registrations under this label therefore mix decades-old standard-of-care protocols with newer autoimmune-reset trials, and the risk profile is nothing like that of an outpatient infusion.

The numbers

Every figure below comes from one reproducible query (type 1 diabetes x hematopoietic stem cell transplantation) run against ClinicalTrials.gov API v2 on 2026-08-29.

How mature is this evidence?

Later-phase work exists but is not dominant (1 of 14), which is the typical profile of a field that has shown safety and is still testing whether benefit survives a control arm.

Completion status: 6 completed, 2 stopped early (14% of all records). A registration is a plan, not a result.

Median planned enrolment is 25 participants (largest single study: 100). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.

Where the studies are

Country coverage runs to 8, but the distribution has a long tail behind China at about 31% of mentions.

Legal pathway differs by country — see where cell therapy is legal, by country.

Who runs them

The sponsor mix is academic (6 academic or hospital, 2 commercial among the most frequent lead sponsors).

• The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School — 2 records
• University of Sao Paulo — 2 records
• Ain Shams University — 1 record
• Uppsala University Hospital — 1 record
• Dra. Olga Graciela Cantu Rodriguez — 1 record
• Adistem Ltd — 1 record

Representative registered studies

Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.

What this page does and does not tell you

These figures describe effort, not outcome. Published results, with their control arms and endpoints, are where benefit is decided.

If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.

Frequently asked

How many HSCT studies for Diabetes (Type 1 & 2) are recruiting right now?

2 of 14 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.

Is HSCT an approved treatment for Diabetes (Type 1 & 2)?

Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 14 registered studies tell you research exists, not that a product cleared review.

How advanced is the research on HSCT for Diabetes (Type 1 & 2)?

1 of 14 records carry a Phase 3 or Phase 4 label and 6 are marked completed. Registrations run from 2003 to 2025.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.